Equities research analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for Aardvark Therapeutics in a report released on Monday, March 10th. Cantor Fitzgerald analyst J ...

Investment analysts at Bank of America began coverage on shares of Aardvark Therapeutics (NASDAQ:AARD – Get Free Report) in a note issued to investors on Monday, MarketBeat reports. The firm set a ...

RBC Capital analyst Brian Abrahams initiated coverage of Aardvark Therapeutics (AARD) with an Outperform rating and $21 price target Aardvark ...

BofA initiated coverage of Aardvark Therapeutics (AARD) with a Buy rating and $22 price target The company’s lead drug ARD-101 is in Phase 3 ...

We recently published a list of 10 Stocks With At Least $10 Million In Insider Spending Recently. In this article, we are ...

Aardvark Therapeutics has raised $94.2m in an initial public offering (IPO) to support the development of its hunger-suppressing drug ARD-101 for the rare disease Prader-Willi syndrome.

While Aardvark Therapeutics is interested in serving this market, first it wants to validate its approach by treating patients whose excessive eating is rooted in a rare genetic disorder.

Obesity-focused Aardvark Therapeutics is heading to the Nasdaq this morning in an IPO that matched the low end of its expectations. The company’s 5.9 million shares will be offered at $16 apiece ...

Shares of obesity drug developer Aardvark Therapeutics (NASDAQ:AARD) closed 11% lower following the company's $94M initial public offering. Aardvark (NASDAQ:AARD) shares opened at $15.18 after ...